Lesson 6,
Topic 7
In Progress
Key Guidelines and Evidence
Lesson Progress
0% Complete
- AAP Guidelines on Palivizumab Prophylaxis (Pediatrics 2014)
- Palivizumab prophylaxis recommendations for high-risk infants
- Maximum 5 monthly doses; no routine use beyond age 24 months
- Moderate recommendation, high quality evidence
- AAP Guidelines on Ribavirin (Pediatrics 2006)
- Ribavirin lacks efficacy for RSV lower respiratory tract disease
- Routine use not recommended
- Strong recommendation, moderate quality evidence
- Cochrane Review (2021)
- Bronchodilators have limited efficacy for RSV bronchiolitis
- Routine use not recommended
- High quality evidence